bisbenzimidazole and quinazolines

bisbenzimidazole has been researched along with quinazolines in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jackman, AL; Ormerod, MG; Skelton, LA; Titley, JC	1
Chen, L; He, Y; Huang, H; Liao, H; Wei, W	1

Other Studies

2 other study(ies) available for bisbenzimidazole and quinazolines

Article	Year
Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry, 1998, Sep-01, Volume: 33, Issue:1 Topics: Animals; Bisbenzimidazole; Bromodeoxyuridine; Cell Cycle; Cell Division; DNA, Neoplasm; Flow Cytometry; Folic Acid; Folic Acid Antagonists; Growth Inhibitors; Humans; Mice; Propidium; Pyridines; Quinazolines; Staining and Labeling; Thymidylate Synthase; Tumor Cells, Cultured	1998
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides	2008

Article

Year

Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action.

Cytometry, 1998, Sep-01, Volume: 33, Issue:1

Topics: Animals; Bisbenzimidazole; Bromodeoxyuridine; Cell Cycle; Cell Division; DNA, Neoplasm; Flow Cytometry; Folic Acid; Folic Acid Antagonists; Growth Inhibitors; Humans; Mice; Propidium; Pyridines; Quinazolines; Staining and Labeling; Thymidylate Synthase; Tumor Cells, Cultured

1998

Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.

Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:2

Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides

2008